Kyverna Completes First-Ever Autoimmune CAR-T BLA Filing, Seeks Priority Review in Stiff Person Syndrome
KYTX sits 16% above its 52-week low of $4.495.
Summary
Kyverna finished its rolling BLA for miv-cel in stiff person syndrome and asked the FDA for priority review under its RMAT designation. If approved, miv-cel would be the first therapy approved for SPS and the first CAR-T approved in autoimmune disease — a genuine first-in-class position. The filing rests on the KYSA-8 registrational data reported in September and the one-year durability results presented at MS Toronto in October, so the clinical package is already public; what's new is that the application is now in the FDA's hands. The company is staffing up commercial leadership and field infrastructure ahead of a potential 2027 launch. Q3 cash stood at $170.6M with runway into 2028, and the net loss was $41.9M ($0.68 per share). Kyverna also shelved the KYV-102 program to concentrate spending on miv-cel. Next hard checkpoint is FDA acceptance and the priority-review decision; gMG enrollment is guided to finish mid-2027.
At the time of this announcement, KYTX was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $316.6M. The 52-week trading range was $4.50 to $13.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.